CINCINNATI, OH--(Marketwire - 04/06/10) - Medpace, a privately held, global, full-service clinical research organization (CRO) announced that it has acquired Symbios Clinical, a CRO dedicated to medical device clinical trials with expertise in pre-market, post-approval and post-market / outcomes trials. Symbios supports the full spectrum of medical device trials.
This acquisition allows the integration of Medpace’s therapeutic expertise and global reach with the device expertise of Symbios to offer best-in-class clinical trial management solutions to medical device companies. Medpace currently offers full service strategic consultation, Phase I-IV clinical trial management, bio-imaging, central laboratory, clinical pharmacology, and bioanalytical support for pharmaceutical and biotechnology companies, which Symbios will be now able to leverage to complement their service offering for medical device companies as well.
Symbios was founded and is currently led by Chief Executive Officer Ryan Wilson, BS, MBA, and Managing Partner, Ethan Rooney, BS, MBA. The Symbios management team brings extensive experience in medical device research. Ryan Wilson, along with his current management team, will continue to lead Symbios Clinical as a member of the Medpace group of companies.
“I am pleased to welcome Ryan Wilson and the Symbios team to Medpace as the head of our medical device business,” said Dr. August Troendle, President and CEO, Medpace. “Ryan and his team have built a successful company in the growing area of medical device research. They hold a unique position as a CRO dedicated to conducting medical device trials. The ability of Medpace to tap into this innovative company for benefit of our existing and new Sponsors will be valuable as yet another service area for Medpace, and allow Symbios to benefit from our established global infrastructure.”
Symbios was advised by Fairmount Partners in this transaction. Symbios Clinical is located in Minneapolis, Minnesota and will continue to operate out of that area.
ABOUT MEDPACE
Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry’s most experienced and therapeutically focused teams to execute at every level of the company’s operations, providing complete and seamless drug development services. In June 2009 Medpace was rated as the best CRO by U.S. Investigators in the 2009 CenterWatch Site Survey.
Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.
With 900+ employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, and central image management and reading from Imagepace.
Visit the Medpace website at: www.medpace.com
ABOUT SYMBIOS CLINICAL
Symbios Clinical is a CRO for medical devices founded in 2006 in the Minneapolis, Minnesota area. Symbios offers trial design, site management, project management, monitoring, and data management for companies with medical devices in the clinical trial phase. Symbios has the ability to conduct medical device clinical trials for small or large sponsors in the US and in Europe. Symbios has therapeutic experience in multiple device therapies including various cardiovascular and metabolic diseases.
Visit Symbios Clinical at: www.symbiosclinical.com
Contact: Mary Kuramoto +1 513-579-9911 X 2523 m.kuramoto@medpace.com
